A new trading day began on Monday, with Pacific Biosciences of California Inc (NASDAQ: PACB) stock price down -4.35% from the previous day of trading, before settling in for the closing price of $1.38. PACB’s price has ranged from $0.85 to $2.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -23.55% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -52.90%. With a float of $264.44 million, this company’s outstanding shares have now reached $300.35 million.
In an organization with 575 employees, it is important to assess its efficiency.
Pacific Biosciences of California Inc (PACB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc is 11.96%, while institutional ownership is 55.94%. The most recent insider transaction that took place on Aug 18 ’25, was worth 35,182. In this transaction an insider of this company sold 26,836 shares at a rate of $1.31, taking the stock ownership to the 1,920,035 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Officer proposed sale 26,836 for $1.31, making the entire transaction worth $35,174.
Pacific Biosciences of California Inc (PACB) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.17 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -52.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.08% during the next five years compared to -23.55% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Here are Pacific Biosciences of California Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.27, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc (PACB)
Let’s dig in a bit further. During the last 5-days, its volume was 5.41 million. That was inferior than the volume of 9.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 62.57%.
During the past 100 days, Pacific Biosciences of California Inc’s (PACB) raw stochastic average was set at 51.65%, which indicates a significant increase from 41.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1129 in the past 14 days, which was higher than the 0.1063 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3802, while its 200-day Moving Average is $1.4818. However, in the short run, Pacific Biosciences of California Inc’s stock first resistance to watch stands at $1.3600. Second resistance stands at $1.4000. The third major resistance level sits at $1.4200. If the price goes on to break the first support level at $1.3000, it is likely to go to the next support level at $1.2800. The third support level lies at $1.2400 if the price breaches the second support level.
Pacific Biosciences of California Inc (NASDAQ: PACB) Key Stats
With a market capitalization of 396.49 million, the company has a total of 300,371K Shares Outstanding. Currently, annual sales are 154,010 K while annual income is -309,850 K. The company’s previous quarter sales were 39,770 K while its latest quarter income was -41,930 K.
